Might haplo "be the (better) match"?

Blood. 2016 Feb 18;127(7):799-800. doi: 10.1182/blood-2016-01-689042.

Abstract

In this issue of Blood, in a registry study by Kanate et al of reduced-intensity conditioning allogeneic blood or marrow transplantation (BMT) outcomes for lymphoma, HLA-haploidentical (haplo) transplantation with posttransplantation cyclophosphamide (PTCy) is associated with similar rates of relapse and survival as HLA-matched unrelated donor (MUD) transplantation but lower rates of grades III to IV acute and chronic graft-versus-host disease (GVHD).

Publication types

  • Comment

MeSH terms

  • Antilymphocyte Serum / administration & dosage*
  • Cyclophosphamide / administration & dosage*
  • Female
  • Graft vs Host Disease*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lymphoma*
  • Male
  • Transplantation Conditioning*
  • Unrelated Donors*

Substances

  • Antilymphocyte Serum
  • Cyclophosphamide